Expression of PRAD1/cyclin D1 in plasma cell malignancy: incidence and prognostic aspects

Br J Haematol. 1999 Mar;104(3):614-7. doi: 10.1046/j.1365-2141.1999.01204.x.


We analysed PRAD1/cyclin D1 expression in 20 patients with plasma cell malignancy by Northern analysis. 6/17 multiple myeloma patients and 3/3 plasma cell leukaemia patients showed PRAD1/cyclin D1 expression. This incidence appeared to be higher than the expected incidence based on previous studies. Southern analysis did not show rearrangement of the bcl-1 region. Although there was no statistical difference, the PRAD1/cyclin D1 negative group showed a 1-year survival of 81.8%, 3-year survival of 45.5% and 5-year survival of 22.7%, and those for the PRAD1/cyclin D1 positive group were 63.5%, 16.9% and 16.9%, respectively. Further study is required to determine whether PRAD1/cyclin D1 expression is a prognostic factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blotting, Southern
  • Cyclin D1 / metabolism*
  • Female
  • Humans
  • Leukemia, Plasma Cell / metabolism*
  • Male
  • Middle Aged
  • Multiple Myeloma / metabolism*
  • Prognosis
  • Survival Analysis


  • Cyclin D1